Glucagon-Like Peptide-1 Agonists or Tezepelumab for Obesity-Associated Asthma: A Cohort Study

Authors: Staggers, Kristen A; Minard, Charles; McCormack, Meredith C; Cahill, Katherine N; Wu, Tianshi David

Source journal: American journal of respiratory and critical care medicine (2026-11-19)

DOI: 10.1093/ajrccm/aamag613

Abstract

RATIONALE: Obesity is associated with poor asthma outcomes. GLP-1 and dual GLP-1/GIP receptor agonists induce weight loss and dampen airway inflammation independent of pathways currently targeted by biologics. OBJECTIVE: To compare differences in respiratory outcomes and weight loss between GLP-1-based medications and tezepelumab in asthma patients without diabetes. METHODS: A retrospective study was performed in a multi-institutional electronic health record database. Patients with specialist-treated, obesity-associated, moderate-to-severe asthma with at least one severe exacerbation in the prior year who initiated liraglutide, semaglutide, tirzepatide, or tezepelumab between January 1, 2022 and December 31, 2025 were identified. Prevalent diabetes was excluded. Patients were followed for subsequent exacerbations, rescue inhaler prescriptions, respiratory-related healthcare encounters, and time to greater than 10% loss in body mass index. Overlap weighting accounted for imbalance in baseline asthma and obesity characteristics. RESULTS: 2779 patients were identified, of whom 133 initiated liraglutide, 1770 semaglutide, 472 tirzepatide, and 404 tezepelumab. In weighted estimates, patients starting tirzepatide experienced a lower hazard of severe exacerbation compared to tezepelumab (weighted hazard ratio [wHR] 0.41; 95% confidence interval [CI] 0.24-0.70); those starting semaglutide had a similar hazard (wHR 0.99; 95% CI 0.70-1.39). Tirzepatide and semaglutide initiators attained >10% reduction in BMI sooner, had less need for rescue inhalers, and had fewer subsequent respiratory-related encounters compared to tezepelumab. CONCLUSIONS: GLP-1-based medications, and in particular dual-incretin GLP-1/GIP receptor agonists, may have comparable effectiveness to biologic therapy among patients with associated obesity without diabetes. Clinical trials are necessary to validate findings in this observational study.

Read the full text

Related topics

Related open access articles

Abstract and bibliographic data from PubMed (U.S. National Library of Medicine). Copyright of the abstract belongs to the original publisher or authors.